Efficacy and safety of CalliSpheres® microspheres-based drug-eluting beads transaterial chemoembolization in the treatment of hepatocellular carcinoma

Abstract

Abstract: Objective To evaluate the treatment response, survival benefit, change of liver function and adverse events (AEs) of CalliSpheres^® (CSM) based drug-eluting beads transarterial chemoembolization (DEB-TACE) in treating hepatocellular carcinoma (HCC). Methods Sixty-six HCC patients who underwent CSM-based DEB-TACE in the Second Affiliated Hospital of Nanchang University were consecutively enrolled in this retrospective cohort study. The baseline characteristics of HCC patients were recorded. Treatment responses at 1 month after treatment, liver function related laboratory indexes pre and post-treatment, and the post-treatment AEs were recorded. Disease-free survival (DFS) and overall survival (OS) were documented and evaluated. Results Complete response (CR), Overall Response Rate (ORR) and Disease Control Rate (DCR) within 1 month post treatment were 18.2%, 75.8%, and 93.9%, respectively. Subgroup analysis revealed that patient with higher Child-Pugh stage (B stage 50.0% vs A stage 80.4%, P=0.039) and higher BCLC stage (C stage 40.0% vs B stage 82.4% vs A stage 94.1%, P=0.001) had worse ORR. The median PFS and OS were 6.0 months and 20.0 months, respectively. Subgroup analysis disclosed that patients with Child-Pugh B and higher BCLC C had both shorter DFS (P=0.015 and P=0.009), as well as worse OS (P=0.018 and P=0.002); additionally, the patients with multifocal disease had worse DFS (P=0.007). The Alb (median 34.7 g/L vs 37.7 g/L, P<0.001) and Scr (median 66.7 μmol/L vs 70.7 μmol/L, P=0.016) level decreased, while TBil (median 20.4 μmol/L vs. 16.8 μmol/L, P=0.025) increased after treatment. Other liver function-related indexes did not change after treatment. The most common AEs post treatment was pain (incidence rate of 47.0%). Conclusion CSM based DEB-TACE achieves favorable treatment response and survival benefit in Chinese HCC patients, also with good tolerance. Several clinical features might have the potentials to serve as prognostic markers.

Key words: Hepatocellular, Transarterial chemoembolization, Drug-eluting beads, Efficacy, Safety

ZHENG Ya-lu, XIONG Kai, SHI Qing, YANG Hui, ZHENG Xiong. Efficacy and safety of CalliSpheres^® microspheres-based drug-eluting beads transaterial chemoembolization in the treatment of hepatocellular carcinoma[J]. Chinese Hepatolgy, 2024, 29(10): 1194-1199.

References

[1] Wong MC, Jiang JY, Goggins WB, et al. International incidence and mortality trends of liver cancer: a global profile [J]. Sci Rep, 2017, 7: 45846.
[2] Sherman M. Surveillance for hepatocellular carcinoma [J]. Best Pract Res Clin Gastroenterol, 2014, 28(5): 783-793.
[3] Guan MC, Wang MD, Liu SY, et al. Early diagnosis and therapeutic strategies for hepatocellular carcinoma: From bench to bedside [J]. World J Gastrointest Oncol, 2021, 13(4): 197-215.
[4] Song T, Li L, Wu S, et al. Peripheral Blood Genetic Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma [J]. Front Oncol, 2021, 11: 583714.
[5] Bzeizi KI, Abdullah M, Vidyasagar K, et al. Hepatocellular Carcinoma Recurrence and Mortality Rate Post Liver Transplantation: Meta-Analysis and Systematic Review of Real-World Evidence [J]. Cancers (Basel), 2022, 14(20): 5114.
[6] Forner A, Reig M, Bruix J. Hepatocellular carcinoma [J]. Lancet, 2018, 391(10127): 1301-1314.
[7] Daniell KM, Banson KM, Diamond BH, et al. Approach to Stereotactic Body Radiotherapy for the Treatment of Advanced Hepatocellular Carcinoma in Patients with Child-Pugh B-7 Cirrhosis [J]. Curr Treat Options Oncol, 2022, 23(12):1761-1774.
[8] Zhang L, Sun J, Wang K, et al. First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review [J]. Curr Oncol, 2022, 29(10): 7305-7326.
[9] Imai N, Ishigami M, Ishizu Y, et al. Transarterial chemoembolization for hepatocellular carcinoma: A review of techniques [J]. World J Hepatol, 2014, 6(12): 844-850.
[10] Bzeizi KI, Arabi M, Jamshidi N, et al. Conventional Transarterial Chemoembolization Versus Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis [J]. Cancers (Basel), 2021, 13(24):6172.
[11] Razi M, Jianping G, Xu H, et al. Conventional versus drug-eluting bead transarterial chemoembolization: A better option for treatment of unresectable hepatocellular carcinoma [J]. J Interv Med, 2021, 4(1): 11-14.
[12] Zhang S, Huang C, Li Z, et al. Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres Beads in rabbit livers [J]. Drug Deliv, 2017, 24(1): 1011-1017.
[13] Shiozawa K, Watanabe M, Ikehara T, et al. Efficacy of intra-arterial contrast-enhanced ultrasonography during transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma [J]. World J Hepatol, 2018, 10(1): 95-104.
[14] Aliberti C, Carandina R, Lonardi S, et al. Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center [J]. J Vasc Interv Radiol, 2017, 28(11): 1495-1502.
[15] Liu Y, Huang W, He M, et al. Efficacy and safety of CalliSpheres(R) drug-eluting beads transarterial chemoembolization in Barcelona Clinic Liver Cancer stage C patients [J]. Oncol Res, 2018, 27(5):565-573.
[16] Zhou GH, Han J, Sun JH, et al. Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by CalliSpheres(R) beads in Chinese hepatocellular carcinoma patients [J]. BMC Cancer, 2018, 18(1): 644.
[17] Facciorusso A, Mariani L, Sposito C, et al. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma [J]. J Gastroenterol Hepatol, 2016, 31(3): 645-653.
[18] Cheung AH, Lam CS, Tam HS, et al. Nine-year experience of doxorubicin-eluting beads chemoembolization for hepatocellular carcinoma [J]. Hepatobiliary Pancreat Dis Int, 2016, 15(5): 493-498.
[19] Zhang X, Zhou J, Zhu DD, et al. CalliSpheres(R) drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study [J]. Clin Transl Oncol, 2018, 21(2):167-177.
[20] Sanchez-Delgado J, Vergara M, Machlab S, et al. Analysis of survival and prognostic factors in treatment of hepatocellular carcinoma in Spanish patients with drug-eluting bead transarterial chemoembolization [J]. Eur J Gastroenterol Hepatol, 2018, 30(12): 1453-1460.
[21] Reis SP, Sutphin PD, Singal AG, et al. Tumor Enhancement and Heterogeneity Are Associated With Treatment Response to Drug-Eluting Bead Chemoembolization for Hepatocellular Carcinoma [J]. J Comput Assist Tomogr, 2017, 41(2): 289-293.
[22] Facciorusso A. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art [J]. World J Gastroenterol, 2018, 24(2): 161-169.
[23] Song JE, Kim DY. Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma [J]. World J Hepatol, 2017, 9(18): 808-814.
[24] Chen P, Yuan P, Chen B, et al. Evaluation of drug-eluting beads versus conventional transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis [J]. Clin Res Hepatol Gastroenterol, 2017, 41(1): 75-85.
[25] Ni JY, Sun HL, Chen YT, et al. Drug-eluting bead transarterial chemoembolization in the treatment for unresectable soft tissue sarcoma refractory to systemic chemotherapy: a preliminary evaluation of efficacy and safety [J]. J Cancer Res Clin Oncol, 2018, 144(1): 157-163.
[26] Kitajima Y, Takahashi H, Akiyama T, et al. Supplementation with branched-chain amino acids ameliorates hypoalbuminemia, prevents sarcopenia, and reduces fat accumulation in the skeletal muscles of patients with liver cirrhosis [J]. J Gastroenterol, 2018, 53(3): 427-437.

Efficacy and safety of CalliSpheres^® microspheres-based drug-eluting beads transaterial chemoembolization in the treatment of hepatocellular carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	CHEN Yuan-li, ZENG De-feng, FAN Hui-wen. The value of contrast-enhanced ultrasound combined with ultrasound elastography in predicting microvascular invasion of hepatocellular carcinoma [J]. Chinese Hepatolgy, 2024, 29(9): 1035-1039.
[2]	ZHU Ji-lan, ZHAO Xia, WANG Shi-wei, YANG Lei. The predictive value of multiparametric magnetic resonance imaging combined with CT dynamic enhancement on the efficacy of immunotherapy for patients with advanced hepatocellular carcinoma [J]. Chinese Hepatolgy, 2024, 29(9): 1040-1046.
[3]	QIN Si-wei, ZHU Xiao-qiang, XU Lei-lei, LUO Xin. A comparison between TACE combined with sorafenib or ¹²⁵I seed implantation for the treatment of hepatocellular carcinoma patients with portal vein tumor thrombus and arteriovenous fistula [J]. Chinese Hepatolgy, 2024, 29(9): 1052-1055.
[4]	LIU Cui-cui, HE Yi, QIU Jing-qi, LIANG Shuang, WANG Qian, ZHANG Zhi-bo. The significance of contrast-enhanced ultrasound in assessing hepatocellular carcinoma in cirrhotic patients and its association with serum levels of AFP-L3, GPC3 and GP73 [J]. Chinese Hepatolgy, 2024, 29(9): 1056-1059.
[5]	YANG Zi-jun, YANG Jia-xin, GUO Li-li. The value of DCE-MRI combined with enhanced CT scan in evaluating the treatment effect of TACE on patients with primary hepatocellular carcinoma [J]. Chinese Hepatolgy, 2024, 29(9): 1060-1063.
[6]	WANG Guo-feng, JIA Yu-qing, SHU Chang-xin, CAI Xiao-dong, WANG Hong-bo, XU Jian-hong. A clinical comparison of open anatomical hepatectomy with different approaches for the treatment of hepatocellular carcinoma [J]. Chinese Hepatolgy, 2024, 29(9): 1064-1067.
[7]	BAI Ling, YIN Hui-kang, GE Qi, GENG Cheng-jun. MRI combined with DWI and DCE scanning sequences to evaluate hepatitis B hepatocellular carcinoma and differentiate it from benign lesions with rich blood supply in the liver [J]. Chinese Hepatolgy, 2024, 29(8): 952-955.
[8]	LIAO Zhong-yang, LI Hang, CHEN Yong-song. Evaluation of imaging differences in different molecular subtypes of hepatocellular adenoma [J]. Chinese Hepatolgy, 2024, 29(8): 960-964.
[9]	JING Chang-you, ZHU Tong, ZHANG Yong-hong, LI Jian-jun. The time interval between TACE and ablation therapy: A single-center retrospective study on the treatment efficacy for early stage hepatocellular carcinoma [J]. Chinese Hepatolgy, 2024, 29(7): 777-801.
[10]	QIAN Ye-qiang, GAO Lu, YU Chun-lai. An analysis on the short-term and long-term therapeutic effects of tyrosine kinase inhibitors combined with hepatic artery chemoembolization for the treatment of hepatocellular carcinoma [J]. Chinese Hepatolgy, 2024, 29(7): 780-783.
[11]	ZHANG Yun-jiang, LIANG Liang, ZHANG Dong-cheng. The alpha-fetoprotein response and its prognostic evaluation value for patients with advanced hepatocellular carcinoma treated with karelizumab in combination with sorafenib [J]. Chinese Hepatolgy, 2024, 29(7): 784-787.
[12]	DUAN Chang-hu, DUAN Jian-feng, WU Lin, TAI Sheng, LIU Xiao-chen. An analysis on the efficacy of sequential surgical resection for initial unresectable hepatocellular carcinoma treated with interventional therapy combined with targeted immunotherapy [J]. Chinese Hepatolgy, 2024, 29(7): 788-793.
[13]	YU Jian, DONG Wen-jian, XIA Jian-xin, PENG Ren-cong. Performance of sound velocity matching technique and shear wave elastography in differentiating atypical hepatic hemangioma from primary hepatocellular carcinoma in 60 patients [J]. Chinese Hepatolgy, 2024, 29(7): 798-801.
[14]	FU Peng, TANG Ya-dan, YANG Fang-fang, YANG Li-xin. Contrast-enhanced ultrasound perfusion characteristics of different nodules in hepatitis B-related cirrhosis [J]. Chinese Hepatolgy, 2024, 29(7): 813-816.
[15]	CHEN Jie, XU Chao-li, LIU Hong. An analysis on the clinical efficacy and prognostic factor of hepatectomy and local ablation treatment for recurrent hepatitis B-related hepatocellular carcinoma after surgery [J]. Chinese Hepatolgy, 2024, 29(6): 648-651.